Key result
Early therapeutic anticoagulation linked to ~86% lower risk of recurrent stroke in AF.
Why the study?
Patients with acute cardio-embolic stroke from atrial fibrillation are at high risk for early recurrent stroke, but early anti-coagulation safety and efficacy remain uncertain.
Cohort (n=324)
No
Answers are grounded in this paper and cite their sources.
May support early anticoagulation in acute stroke with AF; hypothesis-generating and requires RCTs before practice change.
BACKGROUND: Patients with acute cardio-embolic stroke from atrial fibrillation (AF) are at risk for recurrence with up to 50% of recurrent stroke occurring within two weeks of the index event. Anti-coagulation with heparinoids within 48 hours of stroke has been shown to increase risk of symptomatic intracranial hemorrhage (ICH) with no clear benefit on early stroke recurrence. METHODS: This study was a retrospective chart review of consecutive patients who were admitted to the stroke service at the Foothills Medical Centre between 2009 and 2011. All patients with an acute stroke with a cardio-embolic etiology and a diagnosis of atrial fibrillation were reviewed. We hypothesized that anti-coagulation within two weeks of stroke, appropriately begun because of a diagnosis of AF, decreased rates of recurrent stroke without causing an increase in rates of symptomatic ICH. RESULTS: Between 2009-2011, 324 patients were identified with cardio-embolic stroke secondary to AF. Within two weeks of stroke onset 61.4% (199/324) of patients were therapeutic on anti-coagulation. Patients who were anti-coagulated had a smaller median index stroke volume (3.2 ml vs 18.4 ml). Three (0.9%) patients suffered a clinically significant ICH. Recurrent stroke occurred in 11 patients (3.4%) within the two-week period. Therapeutic anti-coagulation within two weeks of initial stroke was associated with a decreased risk of recurrent stroke (RR 0.1, 95% CI 0.03-0.64). CONCLUSIONS: Anti-coagulation within two weeks of acute stroke in patients with AF appears to be safe among patients with smaller infarcts and prevents early recurrent infarction.
No takes yet. Share an insight, caveat, or question.
Hahn et al. (2015) conducted a cohort in Acute ischemic stroke with atrial fibrillation (n=324). Therapeutic anti-coagulation within two weeks of stroke vs. No therapeutic anti-coagulation within two weeks was evaluated on Recurrent ischemic stroke within two weeks (RR 0.14, 95% CI 0.03-0.64). Therapeutic anti-coagulation within two weeks of an acute ischemic stroke in patients with atrial fibrillation decreased the risk of early recurrent stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: